Interventional Strategy in Tackling Emerging Non-alcoholic Fatty Liver Disease in Childhood Obesity
Status:
Completed
Trial end date:
2022-01-21
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to investigate the effects of tocotrienol-rich fraction
vitamin E supplementation on liver enzymes in overweight and obese children with
non-alcoholic fatty liver disease as compared to placebo.
The main question[s] it aims to answer are:
1. Does supplementation of tocotrienol-rich fraction vitamin E reduce the level of liver
enzymes and improve liver steatosis in non-alcoholic fatty liver disease among
overweight and obese children?
2. Does tocotrienol-rich fraction vitamin E supplementation improve the level of liver
steatosis by reducing the level of DNA damage?
Participants will :
1. consume daily either a dose of 50 mg of tocotrienol-rich fraction (TRF) vitamin E or a
placebo for 6 months.
2. Routine clinical assessments include weight, height, waist circumference, and BMI.
Fasting glucose, and fasting serum lipid.
3. The following investigations were performed upon recruitment and following 6 months of
intervention: (i) liver biomarker and enzymes; (ii) DNA damage; (iii) TNFα, IL-6 and
IFN-gamma genes; (iv) Fibroscan.